Abstract
Antisense DNA technology is a method to inhibit or downregulate the production of a target protein by using antisense DNA or RNA molecules. An antisense sequence is a DNA or RNA that is perfectly complementary to the target nucleotide sequence present in the cell. There are two possible mechanisms for an antisense effect. The method that relies on targeting of the mRNA is called the antisense strategy. When the double-stranded DNA or genes situated in the nucleus are targeted, the approach is called the antigene strategy. Whereas the antisense strategy is well established with several examples of in vitro and in vivo applications (1), the antigene approach is still in its infancy and our understanding of the mechanism involved is limited. The antisense strategy utilizes the ability of a 100% complementary DNA or RNA sequence to interlock or hybridize with the target mRNA thus inhibiting the translation of the target protein. This inhibition can be achieved either by blocking the binding sites for the 40S ribosomal subunit and for other translation initiation signals. Alternatively, the formation of a double-stranded DNA/RNA complex can render the RNA susceptible to RNase H digestion (2). The antigene approach is based on the binding of an antisense or sense DNA to the complimentary DNA sequence in the nucleus thus forming a triplex structure. This triplex prevents the transcription of the DNA coding sequence into mRNA (2).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Wagner, R. W. (1994) Gene inhibition using antisense oligodeoxy nucleotides. Nature 372, 333ā335.
Helene, C. (1991) Rational design of sequence-specific oncogene inhibitors based on antisense and antigene oligonucleotides. Eur. J. Cancer 27, 1466ā1471.
Stein, C. A. and Cheng, Y.-C. (1993) Antisense oligonucleotides as therapeutic agents-is the bullet really magical? Science 261, 1004ā1012.
Rakoczy, P. E., Lai, M. C., Watson, M., et al. (1996) Targeted delivery of an antisense oligonucleotide in the retina. Uptake, distribution, stability and effect. Antisense Nucleic Acid Drug Dev. 6, 207ā213.
Rakoczy, P. E., Lai, M. C., Vijayasekaran, S., et al. (1996) Initiation of impaired outer segment degradation in vivo using an antisense oligonucleotide. Curr. Eye Res. 15, 119ā123.
Wiederanders, B. and Kirschke, H. (1986) Antibodies to rat liver cathepsins: characterization and use for the identification of enzyme precursors. Biomed. Biochim. Acta. 45, 1421ā1431.
Katz, M. L. and Shanker, M. J. (1989) Development of lipofuscin like fluorescence in the retinal pigment epithelium in response to protease inhibitor treatment. Mech. Ageing Dev. 49, 23ā40.
Rakoczy, P., Demeter, T., Hutchinson, L., et al. (1989) Detection of human papillomavirus type 16 DNA in cervical swabs and formalinfixed, paraffin-embedded squamous cell carcinomas of non-genital tissues using a synthetic oligodeoxynucleotide probe. J. Virolog. Meth. 25, 325ā336.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
Ā© 2001 Humana Press Inc.
About this protocol
Cite this protocol
Rakoczy, P.E. (2001). Antisense DNA Technology. In: Rakoczy, P.E. (eds) Vision Research Protocols. Methods in Molecular Medicineā¢, vol 47. Humana Press. https://doi.org/10.1385/1-59259-085-3:89
Download citation
DOI: https://doi.org/10.1385/1-59259-085-3:89
Publisher Name: Humana Press
Print ISBN: 978-0-89603-837-0
Online ISBN: 978-1-59259-085-8
eBook Packages: Springer Protocols